Premium
Economic assessments in randomized controlled trials
Author(s) -
Bulpitt Christopher J,
Fletcher AstridE
Publication year - 1990
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1990.tb136984.x
Subject(s) - medicine , quality adjusted life year , quality of life (healthcare) , cost–benefit analysis , randomized controlled trial , economic evaluation , indirect costs , auranofin , rheumatoid arthritis , clinical trial , medical costs , intensive care medicine , pharmacoeconomics , stroke (engine) , physical therapy , cost effectiveness , risk analysis (engineering) , health care , economics , ecology , mechanical engineering , nursing , accounting , pathology , engineering , biology , economic growth
When comparing costs and benefits of different medical strategies, costeffectiveness analysis, cost‐utility analysis and cost‐benefit analysis may be used. Both direct and indirect costs and benefits must be considered. Integrating survival with a measure of quality of life such as a health status index permits calculation of quality of life adjusted years of survival (QALYS). In any trial where it is expected that a more expensive treatment is the most effective, a full economic assessment should be made. Examples are provided from the use of verapamil and propranolol in hypertension, naftidrofuryl in stroke and auranofin in the treatment of rheumatoid arthritis.